Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Huntington’s Disease Treatment Market Growth & Trends
The global huntington’s disease treatment market size is expected to reach USD 1,871.2 million by 2030, registering a CAGR of 23.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.
The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.
The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.
However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient’s quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.
Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.
Huntington’s Disease Treatment Market Report Highlights
H. Lundbeck A/S
Teva Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
Hetero
Lupin
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Novartis AG
uniQure NV.
Latus Bio
Huntington’s Disease Treatment Market Growth & Trends
The global huntington’s disease treatment market size is expected to reach USD 1,871.2 million by 2030, registering a CAGR of 23.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.
The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.
The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.
However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient’s quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.
Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.
Huntington’s Disease Treatment Market Report Highlights
- The symptomatic treatment segment accounted for the largest revenue share in 2024 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
- Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
- Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil’s Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure’s AMT-130 (gene therapy)
- North America held the highest revenue share in 2024 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada
H. Lundbeck A/S
Teva Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
Hetero
Lupin
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Novartis AG
uniQure NV.
Latus Bio
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. Distribution Channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment and Distribution Channel Outlook
2.2.2. Regional outlook
2.3. Competitive Insights
CHAPTER 3. MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising anti-aging burden
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness about anti-aging treatment
3.2.2. Market restraint analysis
3.2.2.1. High cost of development
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Huntington’s Disease Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
CHAPTER 4. HUNTINGTON’S DISEASE TREATMENT MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
4.1. Global Huntington’s Disease Treatment Market: Treatment Dashboard
4.2. Global Huntington’s Disease Treatment Market: Treatment Movement Analysis
4.3. Global Huntington’s Disease Treatment Market by Treatment, Revenue
4.4. Symptomatic Treatment
4.4.1. Symptomatic Treatment market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Disease-modifying Therapies
4.5.1. Disease-modifying Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. HUNTINGTON’S DISEASE TREATMENT MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
5.1. Global Huntington’s Disease Treatment Market: Distribution Channel Dashboard
5.2. Global Huntington’s Disease Treatment Market: Distribution Channel Movement Analysis
5.3. Global Huntington’s Disease Treatment Market by Distribution Channel, Revenue
5.4. Hospital Pharmacy
5.4.1. Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Retail Pharmacy
5.5.1. Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Online Pharmacy
5.6.1. Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. HUNTINGTON’S DISEASE TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY TREATMENT, APPLICATION, AND DISTRIBUTION CHANNEL
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. H. Lundbeck A/S.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Teva Pharmaceutical Industries Ltd.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Treatment benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Bausch Health Companies Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Hetero
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Lupin
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Hikma Pharmaceuticals PLC
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Dr. Reddy’s Laboratories Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Sun Pharmaceutical Industries Ltd.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Novartis AG
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. uniQure NV.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Latus Bio
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. Distribution Channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment and Distribution Channel Outlook
2.2.2. Regional outlook
2.3. Competitive Insights
CHAPTER 3. MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising anti-aging burden
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness about anti-aging treatment
3.2.2. Market restraint analysis
3.2.2.1. High cost of development
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Huntington’s Disease Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
CHAPTER 4. HUNTINGTON’S DISEASE TREATMENT MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
4.1. Global Huntington’s Disease Treatment Market: Treatment Dashboard
4.2. Global Huntington’s Disease Treatment Market: Treatment Movement Analysis
4.3. Global Huntington’s Disease Treatment Market by Treatment, Revenue
4.4. Symptomatic Treatment
4.4.1. Symptomatic Treatment market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Disease-modifying Therapies
4.5.1. Disease-modifying Therapies market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. HUNTINGTON’S DISEASE TREATMENT MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
5.1. Global Huntington’s Disease Treatment Market: Distribution Channel Dashboard
5.2. Global Huntington’s Disease Treatment Market: Distribution Channel Movement Analysis
5.3. Global Huntington’s Disease Treatment Market by Distribution Channel, Revenue
5.4. Hospital Pharmacy
5.4.1. Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Retail Pharmacy
5.5.1. Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Online Pharmacy
5.6.1. Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. HUNTINGTON’S DISEASE TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY TREATMENT, APPLICATION, AND DISTRIBUTION CHANNEL
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. H. Lundbeck A/S.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Teva Pharmaceutical Industries Ltd.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Treatment benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Bausch Health Companies Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Hetero
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Lupin
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Hikma Pharmaceuticals PLC
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Dr. Reddy’s Laboratories Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Sun Pharmaceutical Industries Ltd.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Novartis AG
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. uniQure NV.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Latus Bio
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 3 North America Huntington’s Disease Treatment Market, by Distribution Channel 2018 - 2030 (USD Million)
Table 4 U.S. Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 5 U.S. Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 6 Canada Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 7 Canada Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Mexico Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 9 Mexico Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 10 Europe Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 11 Europe Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Germany Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 13 Germany Huntington’s Disease Treatment Market, by Application, 2018 - 2030 (USD Million)
Table 14 UK Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 15 UK Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 16 France Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 17 France Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 18 Italy Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 19 Italy Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Spain Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 21 Spain Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 22 Asia Pacific Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 24 China Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 25 China Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Japan Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 27 Japan Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 28 India Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 29 India Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 30 South Korea Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 31 South Korea Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Latin America Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 33 Latin America Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Brazil Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 35 Brazil Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 MEA Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 37 MEA Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 South Africa Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 39 South Africa Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Saudi Arabia Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 41 Saudi Arabia Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 42 UAE Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 43 UAE Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Kuwait Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 45 Kuwait Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 3 North America Huntington’s Disease Treatment Market, by Distribution Channel 2018 - 2030 (USD Million)
Table 4 U.S. Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 5 U.S. Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 6 Canada Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 7 Canada Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Mexico Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 9 Mexico Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 10 Europe Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 11 Europe Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Germany Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 13 Germany Huntington’s Disease Treatment Market, by Application, 2018 - 2030 (USD Million)
Table 14 UK Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 15 UK Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 16 France Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 17 France Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 18 Italy Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 19 Italy Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Spain Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 21 Spain Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 22 Asia Pacific Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 23 Asia Pacific Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 24 China Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 25 China Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Japan Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 27 Japan Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 28 India Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 29 India Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 30 South Korea Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 31 South Korea Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Latin America Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 33 Latin America Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Brazil Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 35 Brazil Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 MEA Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 37 MEA Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 South Africa Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 39 South Africa Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Saudi Arabia Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 41 Saudi Arabia Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 42 UAE Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 43 UAE Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 Kuwait Huntington’s Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
Table 45 Kuwait Huntington’s Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Huntington’s Disease Treatment Market Segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment and Distribution Channel segment snapshot
Fig. 10 Distribution Channel segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Pharmaceutical market (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Huntington’s Disease Treatment market: Treatment outlook and key takeaways
Fig. 17 Huntington’s Disease Treatment market: Treatment movement analysis
Fig. 18 Symptomatic Treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Disease-modifying Therapies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Huntington’s Disease Treatment market: Distribution Channel outlook and key takeaways
Fig. 21 Huntington’s Disease Treatment Market: Distribution Channel movement analysis
Fig. 22 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Huntington’s Disease Treatment market revenue, by region, 2024 & 2030, (USD million)
Fig. 26 Regional marketplace: Key takeaways
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 North America Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Key country dynamics
Fig. 30 Target disease prevalence
Fig. 31 U.S. Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Key country dynamics
Fig. 33 Target disease prevalence
Fig. 34 Canada Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Mexico Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 Target disease prevalence
Fig. 38 Europe Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Target disease prevalence
Fig. 41 UK Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Target disease prevalence
Fig. 44 Germany Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence
Fig. 47 France Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 Spain Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Target disease prevalence
Fig. 53 Italy Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Target disease prevalence
Fig. 56 Denmark Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Target disease prevalence
Fig. 59 Sweden Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Target disease prevalence
Fig. 62 Norway Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Asia Pacific Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Target disease prevalence
Fig. 66 Japan Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Target disease prevalence
Fig. 69 China Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Target disease prevalence
Fig. 72 India Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Target disease prevalence
Fig. 75 Australia Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Thailand Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Key country dynamics
Fig. 79 South Korea Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Latin America Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 Target disease prevalence
Fig. 83 Brazil Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Target disease prevalence
Fig. 86 Argentina Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 MEA Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Target disease prevalence
Fig. 90 South Africa Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Target disease prevalence
Fig. 93 Saudi Arabia Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Target disease prevalence
Fig. 96 UAE Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Key country dynamics
Fig. 98 Target disease prevalence
Fig. 99 Kuwait Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Huntington’s Disease Treatment Market Segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment and Distribution Channel segment snapshot
Fig. 10 Distribution Channel segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Pharmaceutical market (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Huntington’s Disease Treatment market: Treatment outlook and key takeaways
Fig. 17 Huntington’s Disease Treatment market: Treatment movement analysis
Fig. 18 Symptomatic Treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Disease-modifying Therapies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Huntington’s Disease Treatment market: Distribution Channel outlook and key takeaways
Fig. 21 Huntington’s Disease Treatment Market: Distribution Channel movement analysis
Fig. 22 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Huntington’s Disease Treatment market revenue, by region, 2024 & 2030, (USD million)
Fig. 26 Regional marketplace: Key takeaways
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 North America Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Key country dynamics
Fig. 30 Target disease prevalence
Fig. 31 U.S. Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Key country dynamics
Fig. 33 Target disease prevalence
Fig. 34 Canada Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Mexico Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 Target disease prevalence
Fig. 38 Europe Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Key country dynamics
Fig. 40 Target disease prevalence
Fig. 41 UK Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Target disease prevalence
Fig. 44 Germany Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence
Fig. 47 France Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 Spain Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 Target disease prevalence
Fig. 53 Italy Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Target disease prevalence
Fig. 56 Denmark Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Target disease prevalence
Fig. 59 Sweden Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Target disease prevalence
Fig. 62 Norway Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Asia Pacific Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Target disease prevalence
Fig. 66 Japan Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Target disease prevalence
Fig. 69 China Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Target disease prevalence
Fig. 72 India Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Target disease prevalence
Fig. 75 Australia Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Thailand Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Key country dynamics
Fig. 79 South Korea Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Latin America Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 Target disease prevalence
Fig. 83 Brazil Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Target disease prevalence
Fig. 86 Argentina Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 MEA Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Target disease prevalence
Fig. 90 South Africa Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Target disease prevalence
Fig. 93 Saudi Arabia Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Target disease prevalence
Fig. 96 UAE Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Key country dynamics
Fig. 98 Target disease prevalence
Fig. 99 Kuwait Huntington’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
